Skip to main content
. 2019 Jun 24;55(6):302. doi: 10.3390/medicina55060302

Table 1.

Association of TGF-β1, Smad2, and Smad4 expression with clinicopathologic features of bladder cancer.

TGF-β1 Smad2 Smad4
Characteristics High p value High p value High p value
Total (n (%)) 404 (100) 275 (68.1) 128 (31.7) 181 (45.2)
Gender
Female 92 (22.8) 70 (25.5) 0.038 27 (21.1) 0.340 45 (24.9) 0.246
Male 312 (77.2) 205 (74.5) 101 (78.9) 136 (75.1)
Tumor grade
Low 148 (36.6) 81 (29.5) <0.001 60 (46.9) 0.003 75 (41.4) 0.048
High 256 (63.4) 194 (70.5) 68 (53.1) 106 (58.6)
Pathologic stage
pTa 97 (24.0) 44 (16.0) <0.001 43 (33.6) <0.001 51 (28.2) 0.003
pT1 195 (48.3) 144 (52.4) 71 (55.5) 95 (52.5)
pT2 112 (27.7) 87 (31.6) 14 (10.9) 35 (19.3)
Carcinoma in situ
Yes 33 (8.2) 25 (9.1) 0.216 11 (8.6) 0.485 11 (6.1) 0.104
No 371 (91.8) 250 (90.9) 117 (91.4) 170 (93.9)
Variant differentiation
Negative 338 (83.7) 228 (82.9) 0.328 115 (89.8) 0.014 155 (85.6) 0.214
Positive 66 (16.3) 47 (17.1) 13 (10.2) 26 (14. 4)
Recurrence
Yes 150 (37.1) 103 (37.5) 0.467 49 (38.3) 0.413 74 (40.9) 0.103
No 254 (62.9) 172 (62.5) 79 (61.7) 107 (59.1)
Cancer-specific death
Yes 138 (34.2) 102 (37.1) 0.043 31 (24.2) 0.003 52 (28.7) 0.022
Other cause 53 (13.1) 34 (12.4) 17 (13.3) 24 (13.3)
Alive 213 (52.7) 139 (50.5) 80 (62.5) 105 (58.0)
Treatment
TURBT ± mitomycin * 67 (16.6) 41 (14.9) 24 (18.8) 31 (17.1) 0.069
Intravesical BCG 186 (46.0) 119 (43.3) 71 (55.4) 0.007 b 89 (49.2)
Cystectomy 72 (17.8) 53 (19.3) 13 (10.2) 0.004 c 26 (14.4)
Chemo/radiotherapy 79 (19.6) 62 (22.5) 0.017 a 20 (15.6) 35 (19.3)

The χ2 test with Yates’ correction was performed; the value of p ≤ 0.05 was considered statistically significant; * transurethral resection with or without intravesical instillation of a single dose of mitomycin; a Chemo/radiotherapy vs other therapy modalities; b BCG (Bacillus Calmette–Guérin vaccine) intravesical vs other therapy modalities; c Radical cystectomy vs other therapy modalities.